


## MS15 TFA

Cat. No.:	HY-151613A
Molecular Formula:	C <sub>66</sub> H <sub>80</sub> F <sub>3</sub> N <sub>11</sub> O <sub>7</sub> S
Molecular Weight:	1228.47
Target:	PROTACs; Akt
Pathway:	PROTAC; PI3K/Akt/mTOR
Storage:	-80°C, protect from light, stored under nitrogen



## SOLVENT & SOLUBILITY

### In Vitro

DMSO : ≥ 100 mg/mL (81.40 mM)

\* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	0.8140 mL	4.0701 mL	8.1402 mL
	5 mM	0.1628 mL	0.8140 mL	1.6280 mL
	10 mM	0.0814 mL	0.4070 mL	0.8140 mL

Please refer to the solubility information to select the appropriate solvent.

## BIOLOGICAL ACTIVITY

### Description

MS15 TFA is a potent and selective AKT PROTAC degrader. MS15 TFA inhibits the AKT1, -2, and -3 activities, with IC<sub>50</sub> values of 798 nM, 90 nM, and 544 nM, respectively<sup>[1]</sup>.

### IC<sub>50</sub> & Target

798 nM (AKT-1), 90 nM (AKT-2), 544 nM (AKT-3)<sup>[1]</sup>

### In Vivo

MS15 (75 mg/kg, IP, once) is bioavailable in mice through intraperitoneal administration<sup>[1]</sup>.  
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## REFERENCES

[1]. Yu X, et al. Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells. *J Med Chem.* 2022 Oct 27;65(20):14237-14260.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA